CORD-19:02a009e42054081b441d0f4b203679c4b0cae38d / 38446-38616 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T268","span":{"begin":0,"end":170},"obj":"Sentence"},{"id":"T72213","span":{"begin":0,"end":170},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Neutralizing antibody production began around the same time, and was robust by Day 30 post infection (14, 557 by PsVNA 50 and 10,240-20,480 by PRNT 50 ) (Fig 8C and 8D )."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T181","span":{"begin":91,"end":100},"obj":"Disease"},{"id":"T92427","span":{"begin":91,"end":100},"obj":"Disease"}],"attributes":[{"id":"A181","pred":"mondo_id","subj":"T181","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A93245","pred":"mondo_id","subj":"T92427","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"Neutralizing antibody production began around the same time, and was robust by Day 30 post infection (14, 557 by PsVNA 50 and 10,240-20,480 by PRNT 50 ) (Fig 8C and 8D )."}